返回 Agenda
IMI PREFER: Patient Perspective in Benefit-Risk Assessments during the Medical Product Life Cycle
Session Chair(s)
Conny Berlin, MS
IMI PREFER Project Leader & Global Head, Quantitative Safety and Epidemiology
Novartis Pharma AG, Switzerland
Patient involvement in development of medicinal products is a topic rapidly evolving. However, how can patient preferences be elicited? Can it be used for regulatory decision making about benefits and risks of medicinal products? This session presents expectations, needs and concerns of different stakeholders and promising approaches how to address these.
Speaker(s)
Exploring and Eliciting Patient Preferences: Why, When and How
Esther De Bekker-Grob
Erasmus University Rotterdam, Netherlands
Associate Professor of Health Economics & Health Preferences, Erasmus School of
Patients as Collaborators in Research
Isabelle Manneh-Vangramberen
European Cancer Patient Coalition (ECPC), Belgium
Head of EU Health & Research Programmes
Patient Preference Studies in Regulatory Decisions: Opportunities and Challenges
Sabine Haubenreisser, PHD, MSC
European Medicines Agency, Netherlands
Principal Scientific Administrator, Stakeholders and Communication Division